TY - JOUR
T1 - Regulatory role of melatonin and BMP-4 in prolactin production by rat pituitary lactotrope GH3 cells
AU - Ogura-Ochi, Kanako
AU - Fujisawa, Satoshi
AU - Iwata, Nahoko
AU - Komatsubara, Motoshi
AU - Nishiyama, Yuki
AU - Yamauchi, Naoko
AU - Inagaki, Kenichi
AU - Wada, Jun
AU - Otsuka, Fumio
N1 - Funding Information:
This work was supported in part by Grants-in-Aid for Scientific Research (No. 24591364 and 15K09434), Foundation for Growth Science and Astellas Foundation for Research on Metabolic Disorders, Japan Foundation for Applied Enzymology (Japan), and The Uehara Memorial Foundation.
Publisher Copyright:
© 2017 Elsevier Inc.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2017/8
Y1 - 2017/8
N2 - The effects of melatonin on prolactin production and its regulatory mechanism remain uncertain. We investigated the regulatory role of melatonin in prolactin production using rat pituitary lactotrope GH3 cells by focusing on the bone morphogenetic protein (BMP) system. Melatonin receptor activation, induced by melatonin and its receptor agonist ramelteon, significantly suppressed basal and forskolin-induced prolactin secretion and prolactin mRNA expression in GH3 cells. The melatonin MT2 receptor was predominantly expressed in GH3 cells, and the inhibitory effects of melatonin on prolactin production were reversed by treatment with the receptor antagonist luzindole, suggesting functional involvement of MT2 action in the suppression of prolactin release. Melatonin receptor activation also suppressed BMP-4-induced prolactin expression by inhibiting phosphorylation of Smad and transcription of the BMP-target gene Id-1, while BMP-4 treatment upregulated MT2 expression. Melatonin receptor activation suppressed basal, BMP-4-induced and forskolin-induced cAMP synthesis; however, BtcAMP-induced prolactin mRNA expression was not affected by melatonin or ramelteon, suggesting that MT2 activation leads to inhibition of prolactin production through the suppression of Smad signaling and cAMP synthesis. Experiments using intracellular signal inhibitors revealed that the ERK pathway is, at least in part, involved in prolactin induction by GH3 cells. Thus, a new regulatory role of melatonin involving BMP-4 in prolactin secretion was uncovered in lactotrope GH3 cells.
AB - The effects of melatonin on prolactin production and its regulatory mechanism remain uncertain. We investigated the regulatory role of melatonin in prolactin production using rat pituitary lactotrope GH3 cells by focusing on the bone morphogenetic protein (BMP) system. Melatonin receptor activation, induced by melatonin and its receptor agonist ramelteon, significantly suppressed basal and forskolin-induced prolactin secretion and prolactin mRNA expression in GH3 cells. The melatonin MT2 receptor was predominantly expressed in GH3 cells, and the inhibitory effects of melatonin on prolactin production were reversed by treatment with the receptor antagonist luzindole, suggesting functional involvement of MT2 action in the suppression of prolactin release. Melatonin receptor activation also suppressed BMP-4-induced prolactin expression by inhibiting phosphorylation of Smad and transcription of the BMP-target gene Id-1, while BMP-4 treatment upregulated MT2 expression. Melatonin receptor activation suppressed basal, BMP-4-induced and forskolin-induced cAMP synthesis; however, BtcAMP-induced prolactin mRNA expression was not affected by melatonin or ramelteon, suggesting that MT2 activation leads to inhibition of prolactin production through the suppression of Smad signaling and cAMP synthesis. Experiments using intracellular signal inhibitors revealed that the ERK pathway is, at least in part, involved in prolactin induction by GH3 cells. Thus, a new regulatory role of melatonin involving BMP-4 in prolactin secretion was uncovered in lactotrope GH3 cells.
KW - Bone morphogenetic protein
KW - Lactotrope
KW - Melatonin
KW - Pituitary
KW - Prolactin
UR - http://www.scopus.com/inward/record.url?scp=85020910948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020910948&partnerID=8YFLogxK
U2 - 10.1016/j.peptides.2017.06.001
DO - 10.1016/j.peptides.2017.06.001
M3 - Article
C2 - 28627372
AN - SCOPUS:85020910948
SN - 0196-9781
VL - 94
SP - 19
EP - 24
JO - Peptides
JF - Peptides
ER -